Phaseline

Companies › Nelum

Nelum: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NLM-001
Hedgehog signaling pathway inhibitor
–Phase 1Pancreatic Ductal Adenocarcinoma–
Zalifrelimab
Cytotoxic T-lymphocyte protein 4 inhibitor
CTLA4Phase 1Pancreatic Ductal Adenocarcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04827953NLM-001Phase 1Pancreatic Ductal AdenocarcinomaOncologyApr 2025
NCT04827953ZalifrelimabPhase 1Pancreatic Ductal AdenocarcinomaOncologyApr 2025

Targets

CTLA4 (1)

Companies with the same targets

AstraZeneca Innovent Biopharmaceutical Technology (Hangzhou) Sichuan Baili Pharmaceutical Summit Therapeutics Revolution Medicines OncoC4 Bristol-Myers Squibb Akeso InxMed (Shanghai) Agenus

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.